Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × TIC10 compound × 90 days × Clear all

Phase

Phase 3 1 Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Specimen Handling 211 pembrolizumab 194 Magnetic Resonance Spectroscopy 172 Biopsy 128 Carboplatin 127 Cyclophosphamide 111 Nivolumab 103 Cisplatin 102 Paclitaxel 97 Radiotherapy 83 Gemcitabine 69 Bevacizumab 66 venetoclax 65 Dexamethasone 63 durvalumab 62 Docetaxel 56 Oxaliplatin 55 fludarabine 53 atezolizumab 53 Ipilimumab 53 Fluorouracil 52 Capecitabine 52 Rituximab 50 Prednisone 49 olaparib 48 Radiation 47 Etoposide 47 Drug Therapy 45 Cytarabine 45 Doxorubicin 43

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06012929 2026-01-26

A Study of ONC201 for Refractory Meningioma

University of Nebraska

Phase 2 Withdrawn

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡